Catalog No.
DHD38502
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20273
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CMC-544, Inotuzumab Ozogamicin, CAS: 1660159-36-3
Clone ID
Inotuzumab
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia, PMID: 27292104
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study, PMID: 29352703
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study, PMID: 30920645
Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia, PMID: 30090971
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial, PMID: 28859185
Inotuzumab ozogamicin for acute lymphoblastic leukaemia, PMID: 31427847
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage, PMID: 30307611
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia, PMID: 30267011
Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease, PMID: 33256906
Inotuzumab Ozogamicin, PMID: 31643242
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden, PMID: 32769965
Inotuzumab Ozogamicin: First Global Approval, PMID: 28819740
Inotuzumab Ozogamicin, PMID: 29999985
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis, PMID: 30985931
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia, PMID: 33098744
Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia, PMID: 29713210
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia, PMID: 33231879
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia, PMID: 30622147
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma, PMID: 31011424
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial, PMID: 31790983
The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal, PMID: 30887470
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study, PMID: 28687420
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin, PMID: 32988266
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study), PMID: 33067614
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia, PMID: 31039409
Immunotherapy in pediatric acute lymphoblastic leukemia, PMID: 31811553
Inotuzumab ozogamicin in acute lymphoblastic leukaemia, PMID: 30956118
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, PMID: 30087554
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia, PMID: 29092647
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia, PMID: 28152223
Adult Acute Lymphoblastic Leukemia, PMID: 27814839
Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia, PMID: 26654587
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia, PMID: 24389139
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, PMID: 30675645
Recent advances in the treatment of acute lymphoblastic leukemia, PMID: 31092071
Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis, PMID: 32646833
Inotuzumab ozogamicin (Besponsa)--an antibody-drug conjugate for ALL, PMID: 29913470
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia, PMID: 26780449
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas, PMID: 25775418
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia, PMID: 22500551
Precision medicine in acute lymphoblastic leukemia, PMID: 33074527
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, PMID: 31186988
Inotuzumab ozogamicin as novel therapy in lymphomas, PMID: 20528256
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults, PMID: 32012891
Inotuzumab ozogamicin, a nonchemotherapy option for relapsed acute lymphoblastic leukemia, PMID: 31188803
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia, PMID: 33815734
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies, PMID: 25304309
Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia, PMID: 29517084
Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia, PMID: 32424837
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions, PMID: 32503572
For research use only. Not for human or drug use.
